Fig. 3From: PROTAC’ing oncoproteins: targeted protein degradation for cancer therapyEarly PROTACs employ peptidic E3 ligase ligands and lack cellular permeability. Targeting ligands and E3 ligase ligands are highlighted in yellow and gray, respectivelyBack to article page